Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biotech company, visits the Nasdaq MarketSite in Times Square. Cullinan will celebrate the 5 th anniversary of its initial public offering ...
In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond ...
The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...
CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...
Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, ...
Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, ...
Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 ...
(RTTNews) - Biotech shares saw strong moves in Friday's after-hours session, with Sarepta leading on upcoming trial data and several peers advancing on recent clinical and regulatory updates. Sarepta ...
VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory ...
In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss: Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech.
(RTTNews) - Kane Biotech Inc. (KNBIF) announced that the U.S. FDA has granted 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, marking a key regulatory milestone for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results